Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success
about
Epigenetic Strategies to Boost Cancer Immunotherapies.Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding affinity.3H-pyrazolo[4,3-f]quinoline haspin kinase inhibitors and anticancer properties.Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.Valproic Acid Exposure of Pregnant Rats During Organogenesis Disturbs Pancreas Development in Insulin Synthesis and Secretion of the Offspring.
P2860
Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success
description
2016 nî lūn-bûn
@nan
2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Histone deacetylase inhibitors ...... explain their limited success
@ast
Histone deacetylase inhibitors ...... explain their limited success
@en
type
label
Histone deacetylase inhibitors ...... explain their limited success
@ast
Histone deacetylase inhibitors ...... explain their limited success
@en
prefLabel
Histone deacetylase inhibitors ...... explain their limited success
@ast
Histone deacetylase inhibitors ...... explain their limited success
@en
P2860
P921
P3181
P356
P1433
P1476
Histone deacetylase inhibitors ...... explain their limited success
@en
P2093
Bryan M Turner
P2860
P304
P3181
P356
10.1002/BIES.201600070
P407
P50
P5008
P577
2016-11-01T00:00:00Z